
## Vivian W Y Liao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1728748/publications.pdf Version: 2024-02-01



VIVIAN WYLIAO

#	Article	IF	CITATIONS
1	The many faces of the adamantyl group in drug design. European Journal of Medicinal Chemistry, 2011, 46, 1949-1963.	5.5	247
2	Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors. British Journal of Pharmacology, 2018, 175, 2911-2925.	5.4	38
3	Gain-of-function variants in <i>GABRD</i> reveal a novel pathway for neurodevelopmental disorders and epilepsy. Brain, 2022, 145, 1299-1309.	7.6	34
4	Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nature Communications, 2022, 13, 1822.	12.8	32
5	A Carbocyclic Curcumin Inhibits Proliferation of Gram-Positive Bacteria by Targeting FtsZ. Biochemistry, 2017, 56, 514-524.	2.5	25
6	Gain-of-function <i>GABRB3</i> variants identified in vigabatrin-hypersensitive epileptic encephalopathies. Brain Communications, 2020, 2, fcaa162.	3.3	21
7	Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic. Journal of Biological Chemistry, 2019, 294, 6157-6171.	3.4	20
8	The Z-Drugs Zolpidem, Zaleplon, and Eszopiclone Have Varying Actions on Human GABAA Receptors Containing γ1, γ2, and γ3 Subunits. Frontiers in Neuroscience, 2020, 14, 599812.	2.8	19
9	Concatenated nicotinic acetylcholine receptors: A gift or a curse?. Journal of General Physiology, 2018, 150, 453-473.	1.9	14
10	Identification of dual PPARα/γ agonists and their effects on lipid metabolism. Bioorganic and Medicinal Chemistry, 2015, 23, 7676-7684.	3.0	12
11	Concatenated Î <sup>3</sup> -aminobutyric acid type A receptors revisited: Finding order in chaos. Journal of General Physiology, 2019, 151, 798-819.	1.9	12
12	Revisiting autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) mutations in the nicotinic acetylcholine receptor reveal an increase in efficacy regardless of stochiometry. Pharmacological Research, 2019, 139, 215-227.	7.1	10
13	Structural mapping of GABRB3 variants reveals genotype–phenotype correlations. Genetics in Medicine, 2022, 24, 681-693.	2.4	10
14	Tubulin-Binding 3,5-Bis(styryl)pyrazoles as Lead Compounds for the Treatment of Castration-Resistant Prostate Cancer. Molecular Pharmacology, 2020, 97, 409-422.	2.3	9
15	Targeting GABAC Receptors Improves Post-Stroke Motor Recovery. Brain Sciences, 2021, 11, 315.	2.3	8
16	Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: Attenuation of potency through resonance effects. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6200-6204.	2.2	7
17	The Synthesis and Evaluation of Fluoroâ€, Trifluoromethylâ€, and Iodomuscimols as GABA Agonists. Chemistry - A European Journal, 2017, 23, 10848-10852.	3.3	7
18	Heterologous expression of concatenated nicotinic ACh receptors: Pros and cons of subunit concatenation and recommendations for construct designs. British Journal of Pharmacology, 2020, 177, 4275-4295.	5.4	6

#	Article	IF	CITATIONS
19	Efficient expression of concatenated α1β2δand α1β3δGABA <sub>A</sub> receptors, their pharmacology and stoichiometry. British Journal of Pharmacology, 2021, 178, 1556-1573.	5.4	6
20	The de novo <i>GABRA4</i> p.Thr300lle variant found in a patient with earlyâ€onset intractable epilepsy and neurodevelopmental abnormalities displays gainâ€ofâ€function traits. Epilepsia, 2022, 63, 2439-2441.	5.1	6
21	Ligand-gated ion channels in genetic disorders and the question of efficacy. International Journal of Biochemistry and Cell Biology, 2020, 126, 105806.	2.8	3